Skip to content

Category Archives: Positioning the Medical Device Start-Up for Success

STOMAPHYX PLUS > Next-Generation Device > Stronger suction capable > Natural Orifice Surgery NOS > Transoral incisionless surgery > EndoGastric Solutions EGS > Incisionless transoral procedures > Treatment of upper gastrointestinal conditions > Gastroesophageal reflux disease GERD > GI conditions > EsophyX > Leading-edge NOS natural orifice surgery products > Proprietary NOS platform technology

Tuesday, July 22, 2008

Does the use of a standard endoscope permit easier clearing of the visual field? Does the higher resolution image allow for even greater precision? Is StomaphyX the future of surgery, and NOS the next step beyond laparoscopy?

IIP > read on here > http://www.endogastricsolutions.com…
…EndoGastric Solutions (EGS), the world leader in natural orifice surgery (NOS) products […]

Filed in Transoral Gastric Volume Reduction TGVR, Transoral Suturing, Transoral Gastric Volume Reduction > Intervention fo, Natural Orifice Translumenal Endoscopic Surgery NOTES, Positioning the Medical Device Start-Up for Success, Transoral Gastric Volume Reduction Intervention Weight , Trends, Transitioning a treatment, Translumenal procedures, Transoral Gastroplasty TOGA, Natural Orifice training course, Transluminal Flexible Endoscopic Procedure, natural orifice, EsophyX, EndoGastric Solutions EGS, CE marked, Cleared by the FDA, GI conditions, STOMAPHYX PLUS, Stronger suction capable, Redmond Washington, Thierry Thaure, Ohio State University, Redwood City California, Julie Ellner, Next-Generation Device, Alvarado Hospital San Diego, Laparoscopic surgeon, Dean Mikami, Proprietary NOS platform technology, Faster And Easier, Transoral incisionless surgery, Natural Orifice Surgery NOS, Pioneer in incisionless transoral procedures, Treatment of upper gastrointestinal conditions, NOS natural orifice surgery products, Leading-edge, Natural orifices tranlumenal endosurgery NOTES, Leak-proof closure, Natural orifices such as the mouth rectum or vagina, Using transoral access, Transoral treatment method, Removal of the appendix or gallbladder via the stomach, Substantial learning curve, Transanal endoscopic microsurgery TEM, Transgastric appendectomy, Transluminal translumenal procedures, Transgastric placement of diaphragm pacing leads, Transgastric surgery, transgastric peritoneoscopy, transgastric cholecystectomy, Natural orifice transluminal endoscopic surgery, translumenal organ resections, transgastric appendectomies, Viscera Stomach Colon Vagina Bladder, Per vagina, Bodies' natural orifices, transgastric biliary endosurgery, transgastric tubal ligation, Reduced risk of adhesions, home by the day after surgery, Orientation for the gastric access puncture, Transoral gastric pouch reduction, Gastroesophageal reflux disease GERD, Natural Orifice Trans Umbilical Surgery NOTUS, Anchor plications, Transoral endoscopic anchor placement system, Navigation inside the stomach and abdominal cavity, Orientation, transgastric retroperitoneal for pancreatic debridement, transgastric appendectomy, transgastric endoscopic splenectomy, Natural Orifice Transluminal Endoscopic Surgery NOTES, Natural Orifice Transgastric Endoscopic Surgery NOTES, per-anal transcolonic, per-oral transgastric, Natural Orifice Transluminal Endoscopic Surgery | Comments Off

Risk Minimization > Positioning the Medical Device Start-Up for Success > Presenting an Investment Opportunity to Venture Capitalists > Various deal stages > Seed > Mezzanine > Maximize Investment Return > Practical Innovation

Wednesday, June 18, 2008

Is the opportunity to present a venture investment prospect rare as life science venture capital firms see hundreds of deals per year? Do VCs only dedicate minutes to screening new proposals and does an entrepreneur only have one chance to pitch a deal successfully? What are the questions an entrepreneur must be prepared for to […]

Filed in Penetrate the market, Historical adoption drivers, Information on how the market may be changing, Investing in labor materials and overhead, Scrap a subpar product, Flexibility, Higher degree of risk minimization, New potential players, Existing competition, Proven medical technology, Live beyond its initial intended purpose, Start-up firm’s strategic position, Ability to forecast, Value inflection points, Identifying the dominant market leaders, Potential exit strategy, Development efficiency, Vital physician feedback at the onset, External engineering design firms, Diligence screening metrics, Truly meeting market need, Outsource part or all of R&D operations, Common for start-up firms, Sound and innovative R&D plan, Make or buy decision, Particular target clinical indication, Applicable market size for the technology, Addressing needs associated with a specific deal, Execution-driven model, Funded start-up, Coupling the prospective end-user, Aligning physician and investor interest, Scrutinized in terms of the real clinical utility, Proactive physician feedback, Conduct pertinent market research, Prioritize end-user needs, Prospective cost of goods, Initial plan for contract manufacturing, In-house effort, Cash flow breakeven and beyond, Get technology to market, Cornerstone of the diligence, Fund operating losses, Financial model, Transfer price, Patent counsel, Understand current intellectual property landscape, Surround technology with more protection, Freedom-to-operate review, Legal counsel collaboration, Intellectual Property Protection, Existing and prospective intellectual property estate, Pro forma financials, Budget, Possessing managerial and multidisciplinary expertise, Roadmap for transitioning the business, From concept to market-leading medical solution, Team of experts, Life sciences firm, Un-manufacturable design, Delay a product launch, Timeline, Milestone plan, Marking requirements, Get the product to market, FDA Food and Drug Administration and CE Conformité Eur, Clear the regulatory approval milestones, Understanding of the financial commitment, Sensitivity analysis, R&D and engineering consume first 18-24 months, Using the invested funds, Attracting venture capital funding, Secure a foothold in the medical market, Ripe for investment, Practical Innovation, Maximize Investment Return, Seed, Mezzanine, High profit potential, Key to success in raising funds, Tight time frame, Return multiple of three to five times, Post-money valuation, Significant return multiples on invested capital, Expectations of its limited partners, Venture capitalists for a medical device start-up, Objectives of the venture capital fund, Various deal stages, Presenting an Investment Opportunity to Venture Capital, See the light of day, Market adoption, Profitability, Differing perspectives, Change the way medicine is practiced, Vision and belief, Potential of innovation, Venture investor, Primary Diligence Drivers, The Bottom Line, Risk Minimization, Positioning the Medical Device Start-Up for Success, Demonstrate Strength in Management, Minimize Risk through Partnerships, Get past go, Regulatory and Reimbursement Approach, Last round of financing, Addressable market in excess of $500 million, Increased efficacy, Reduced morbidity, Enhanced operations management efficiency, Financial perspective, Physician and patient points of view, Unique potential of the technological innovation, Use-incentives, Extrapolated to the patient, Additional benefits, Faster healing times, Financial use incentives, Real diligence, Producing equivalent or better outcomes, Switching from general to local anesthesia, Transitioning a treatment, From invasive surgical procedure to a minimally invasiv, Initial presentation, Build tangible value, Provide at least a 20 percent internal rate of return, Life of the fund, Pre-money valuations, Earn a profit, Venture investor’s principal objective, Venture investors, Advance medicine and help patients, Series A investment, Ownership level in the range of 25-35 percent post-mone, Subsequent rounds of financing, Potentially a higher valuation, Position the company, Introduce venture expertise, Forfeit majority ownership and relinquish control, Attain needed capital, Medical device entrepreneur | Comments Off